通讯作者: 殷军波, qdyjb9131@163.com

DOI：10.12201/bmr.202501.00017

A controlled study of pregabalin combined with escitalopram in patients with major depressive disorder

• 摘要：目的：研究艾司西酞普兰与普瑞巴林联合应用于重度抑郁障碍患者时的临床效果与安全性状况。方法：选取 61 例于2023年6月1日-2024年2月1日青岛市精神卫生中心就诊的重度抑郁障碍患者（Major depressive disorder，MDD）（有 1 例脱落），借助随机数分组方式将其划分为对照组（艾司西酞普兰，n = 30）以及实验组（普瑞巴林联合艾司西酞普兰，n = 30），整个疗程共 6 周。分别在治疗前、治疗第 2 周、第 4 周、第 6 周进行相关评估，并且在治疗前、治疗第 6 周检查血常规、心电图、生化组合，利用汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁 17 项量表 (HAMD - 17)、治疗时出现的症状量表（TESS）对疗效与安全性予以评价。结果：两组患者在入组前的 HAMD - 17、HAMA 得分经比较，其差异无统计学意义 (P > 0.05，t = 0.615)。在治疗 2 周、4 周、6 周后得分均较治疗前有所降低。治疗第 2 周末，实验组 HAMD-17、HAMA 评分显著低于对照组 (P < 0.05)。治疗第 4 周末，实验组 HAMD - 17、HAMA 评分依旧低于对照组 (P < 0.05)。治疗第 6 周末，实验组 HAMD - 17、HAMA 评分同样低于对照组 (P < 0.05)。两组的总不良反应发生率相互比较，差异无统计学意义 (P > 0.05)。结论：普瑞巴林合并艾司西酞普兰对MDD患者可以更快、更有效地缓解焦虑症状及抗抑郁疗效。

  关键词： 普瑞巴林; 艾司西酞普兰 重度抑郁障碍; 广泛性焦虑障碍; 

   

  Abstract: Abstract: To explore the clinical efficacy and safety of escitalopram combined with pregabalin in patients with major depressive disorder. Methods: Sixty patients with recurrent depression were selected and divided into an experimental group (pregabalin combined with escitalopram, n = 30) and a control group (escitalopram, n = 30). The treatment course was 6 weeks. Before treatment and at the 2nd, 4th, and 6th weeks of treatment,Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA), and Treatment Emergent Symptom Scale (TESS) were used to evaluate efficacy and safety. Results: Before enrollment, there was no statistically significant difference in the scores of HAMD-17 and HAMA between the two groups (t = 0.615, P > 0.05).The scores after 2, 4, and 6 weeks of treatment were all lower than those before treatment. At the end of the 2nd week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). At the end of the 4th week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). At the end of the 6th week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Pregabalin combined with escitalopram can relieve anxiety symptoms and have antidepressant efficacy more quickly and effectively in patients with MDD.

  Key words: Pregabalin; Escitalopram; Major Depressive Disorder; Generalised anxiety disorder

  提交时间：2025-01-06

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 王学斐, 陈曼曼, 滕玉欣, 曾波涛. 青少年抑郁症自伤自杀行为与非酶类抗氧化物及甲状腺激素水平分析. 2024. doi: 10.12201/bmr.202412.00022

  武文青, 宋思梦, 王释亮, 伍大华, 谢乐. 周慎教授基于“阴损及阳”理论从肝肾论治迟发性运动障碍经验. 2025. doi: 10.12201/bmr.202509.00038

  任益龙, 蒋春明. 基于孟德尔随机化的25羟维生素D与抽动障碍因果关联研究. 2025. doi: 10.12201/bmr.202507.00007

  黄秋玲, 郁峰, 邹小杰, 徐震. 注意缺陷多动障碍儿童的多动行为与血清促甲状腺激素水平的关系. 2024. doi: 10.12201/bmr.202411.00024

  李祖达, 于淼, 陈尊凡, 王哲, 杨啸林, 徐涛. HMGNet：基于层次化多维特征图卷积网络的孤独症谱系障碍诊断. 2025. doi: 10.12201/bmr.202509.00005

  伍静, 杨青. 清肝宁心制动方治疗儿童注意缺陷多动障碍心肝火旺型的临床观察. 2024. doi: 10.12201/bmr.202412.00051

  邢炳媛, 冯晓娟, 李阳, 闫紫慧, 范志亮. 偏头痛患者心理健康现况研究. 2024. doi: 10.12201/bmr.202408.00034

  林小雷, 马光泛, 陈小珍, 周森. 艾司氯胺酮对乳腺癌患者术后精神状态的影响. 2024. doi: 10.12201/bmr.202412.00054

  丁喜凤, 刘赵朋, 钟颖琦, 郑景辉. 中医药治疗冠心病PCI术后焦虑抑郁的研究进展. 2025. doi: 10.12201/bmr.202503.00078

  张颖, 王业流, 周淑萍. 艾司奥美拉唑联合荜铃胃痛颗粒治疗EPS的临床疗效与安全性研究. 2025. doi: 10.12201/bmr.202501.00052

• 序号	提交日期	编号	操作
  1	2024-12-07	10.12201/bmr.202501.00017V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论